Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient ...

Sensei Biotherapeutics Inc. (NASDAQ:SNSE) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Sensei Biotherapeutics shifted its focus following the acquisition ...

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

(Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced positive topline results from the PIK3CA mutant cohort of the Phase 3 ...

Safety was described as manageable for both doublet and triplet regimens with no new signals, supporting feasibility of comprehensive pathway targeting in metastatic disease. Company plans include an ...

Antioxidant-1 may promote HCC carcinogenesis through the activation of the c-Myb/PI3K/AKT pathway and the inhibition of copper accumulation and oxidative stress. Despite advancements in diagnostic and ...

An international research team has identified a previously unknown mechanism by which the breast cancer drug tamoxifen can increase the risk of secondary tumors in the uterus. The study shows that ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...